T1	Non-query-able 0 47	Participation in other interventional research.
T2	Condition 60 83	penetrating head injury
T3	Condition 96 99	TBI
T4	Value 100 121	more severe than mild
T5	Measurement 125 139	DVBIC criteria
R1	Has_value Arg1:T5 Arg2:T4	
R2	AND Arg1:T3 Arg2:T5	
T6	Qualifier 156 163	primary
T7	Qualifier 167 176	secondary
T8	Condition 177 188	HA disorder
T9	Condition 200 204	PTHA
T10	Negation 189 199	other than
R3	Has_negation Arg1:T9 Arg2:T10	
R4	AND Arg1:T8 Arg2:T9	
*	OR T7 T6
T11	Scope 156 176	primary or secondary
R5	Has_scope Arg1:T8 Arg2:T11	
T12	Observation 206 222	Lifetime history
T13	Multiplier 226 235	5 or more
T14	Condition 236 244	migraine
T15	Qualifier 248 256	probable
T16	Condition 257 265	migraine
R6	Has_qualifier Arg1:T16 Arg2:T15	
*	OR T16 T14
T17	Temporal 276 291	pre-dating mTBI
T18	Procedure 287 291	mTBI
T19	Reference_point 287 291	mTBI
R7	Has_index Arg1:T17 Arg2:T19	
R8	multi Arg1:T19 Arg2:T18	
T20	Scope 236 265	migraine or probable migraine
R9	Has_multiplier Arg1:T20 Arg2:T13	
R10	Has_temporal Arg1:T20 Arg2:T12	
R11	Has_temporal Arg1:T20 Arg2:T17	
T21	Condition 293 296	HAs
T22	Qualifier 312 340	moderate or severe intensity
T23	Multiplier 347 384	average of more than 2 days per month
T24	Temporal 385 416	preceding the concussive trauma
R12	Has_multiplier Arg1:T21 Arg2:T23	
R13	Has_temporal Arg1:T21 Arg2:T24	
R14	Has_qualifier Arg1:T21 Arg2:T22	
T25	Condition 429 432	HAs
T26	Qualifier 418 428	Continuous
R15	Has_qualifier Arg1:T25 Arg2:T26	
T27	Qualifier 452 462	persistent
T28	Multiplier 463 468	daily
T29	Measurement 481 495;514 529	HA-free period between attacks
T30	Value 496 513	less than 8 hours
R16	Has_value Arg1:T29 Arg2:T30	
T31	Negation 478 480	no
R17	Has_negation Arg1:T29 Arg2:T31	
T32	Condition 469 472	HAs
R18	Has_multiplier Arg1:T32 Arg2:T28	
R19	Has_qualifier Arg1:T32 Arg2:T27	
R20	AND Arg1:T32 Arg2:T29	
R21	Subsumes Arg1:T25 Arg2:T32	
T33	Qualifier 532 537	Acute
T34	Qualifier 541 548	serious
T35	Condition 549 564	medical illness
T36	Qualifier 568 576	unstable
T37	Condition 577 600	chronic medical illness
T38	Condition 608 623	unstable angina
T39	Condition 625 646	myocardial infarction
T40	Temporal 647 662	within 6 months
R22	Has_temporal Arg1:T39 Arg2:T40	
T41	Condition 664 688	congestive heart failure
T42	Qualifier 690 712	clinically significant
T43	Qualifier 716 726	concerning
T44	Condition 727 746	cardiac arrhythmias
*	OR T42 T43
T45	Temporal 748 759	preexisting
T46	Condition 760 771	hypotension
T47	Measurement 773 796	systolic blood pressure
T48	Value 796 800	<110
T49	Condition 805 828	orthostatic hypotension
T50	Measurement 830 843	systolic drop
T51	Value 844 853	>20 mm Hg
T52	Temporal 854 874	after 2 min standing
T53	Condition 890 905	lightheadedness
T54	Condition 908 921;933 940	chronic renal failure
T55	Condition 925 940	hepatic failure
T56	Condition 942 960	acute pancreatitis
T57	Condition 962 979	Meniere's disease
T58	Condition 1008 1019	sleep apnea
T59	Qualifier 998 1007	untreated
T60	Non-representable 1022 1220	The eligibility of potential participants having acute serious and/or chronic medical illnesses other than those listed will be evaluated on a case-by-case basis by a study physician, PA-C, or ARNP.
*	OR T34 T33
T61	Scope 532 548	Acute or serious
R23	Has_scope Arg1:T35 Arg2:T61	
R24	Has_qualifier Arg1:T37 Arg2:T36	
T62	Scope 690 726	clinically significant or concerning
R25	Has_scope Arg1:T44 Arg2:T62	
R26	Has_temporal Arg1:T46 Arg2:T45	
R27	Has_value Arg1:T47 Arg2:T48	
R28	Has_value Arg1:T50 Arg2:T51	
R29	Has_temporal Arg1:T50 Arg2:T52	
T63	Scope 830 905	systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness
R30	Subsumes Arg1:T49 Arg2:T63	
R31	Has_qualifier Arg1:T58 Arg2:T59	
R32	Subsumes Arg1:T46 Arg2:T47	
*	OR T46 T49 T54 T55 T56 T57 T58 T39 T38 T41 T44
T64	Scope 608 1019	unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness], chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, or diagnosed but untreated sleep apnea
*	OR T35 T37
T65	Scope 532 600	Acute or serious medical illness or unstable chronic medical illness
R33	Subsumes Arg1:T65 Arg2:T64	
T66	Drug 1229 1237	prazosin
T67	Qualifier 1241 1246	other
T68	Drug 1247 1265	alpha-1 antagonist
T69	Drug 1296 1305	alfuzosin
T70	Drug 1307 1316	doxazosin
T71	Drug 1318 1327	silodosin
T72	Drug 1329 1339	tamsulosin
T73	Drug 1341 1350	terazosin
T74	Temporal 1368 1417	in the 2 weeks prior to initial screen (P1) visit
T75	Reference_point 1392 1417	initial screen (P1) visit
R34	Has_index Arg1:T74 Arg2:T75	
R35	Has_qualifier Arg1:T68 Arg2:T67	
*	OR T66 T68
T76	Scope 1229 1265	prazosin or other alpha-1 antagonist
*	OR T69 T70 T71 T72 T73
T77	Scope 1296 1350	alfuzosin, doxazosin, silodosin, tamsulosin, terazosin
R36	Subsumes Arg1:T76 Arg2:T77	
R37	Has_temporal Arg1:T76 Arg2:T74	
T78	Condition 1455 1462	Allergy
T79	Condition 1475 1491	adverse reaction
T80	Temporal 1466 1474	previous
R38	Has_temporal Arg1:T79 Arg2:T80	
T81	Drug 1495 1503	prazosin
T82	Drug 1513 1531	alpha-1 antagonist
T83	Qualifier 1507 1512	other
R39	Has_qualifier Arg1:T82 Arg2:T83	
*	OR T81 T82
T84	Scope 1495 1531	prazosin or other alpha-1 antagonist
*	OR T78 T79
T85	Scope 1455 1491	Allergy or previous adverse reaction
R40	Has_scope Arg1:T85 Arg2:T84	
T86	Condition 1553 1571	psychotic disorder
T87	Condition 1540 1549	psychosis
T88	Qualifier 1533 1539	Active
T89	Condition 1573 1590	severe depression
T90	Condition 1649 1672	psychiatric instability
T91	Qualifier 1642 1648	severe
R41	Has_qualifier Arg1:T90 Arg2:T91	
T92	Condition 1683 1706	situational life crisis
T93	Qualifier 1676 1682	severe
R42	Has_qualifier Arg1:T92 Arg2:T93	
T94	Condition 1745 1753	suicidal
T95	Condition 1757 1766	homicidal
*	OR T94 T95
*	OR T87 T86 T89 T90 T92
T96	Scope 1745 1766	suicidal or homicidal
R43	Subsumes Arg1:T92 Arg2:T96	
R44	Has_qualifier Arg1:T87 Arg2:T88	
T97	Condition 1868 1890	Substance Use Disorder
T98	Condition 1898 1924	caffeine-related disorders
T99	Negation 1891 1897	except
T100	Condition 1929 1954	tobacco-related disorders
*	OR T98 T100
T101	Scope 1898 1954	caffeine-related disorders, or tobacco-related disorders
R45	Has_negation Arg1:T101 Arg2:T99	
R46	Has_scope Arg1:T97 Arg2:T101	
T102	Measurement 1776 1859	Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria
T103	Value 1770 1775	Meets
R47	Has_value Arg1:T102 Arg2:T103	
R48	AND Arg1:T97 Arg2:T102	
T104	Condition 1968 1976	delirium
T105	Temporal 1977 2002	within the prior 3 months
R49	Has_temporal Arg1:T104 Arg2:T105	
T106	Condition 2004 2012	epilepsy
T107	Condition 2014 2020	stroke
T108	Condition 2022 2030	dementia
T109	Condition 2032 2050	psychotic disorder
T110	Condition 2055 2071	bipolar disorder
*	OR T109 T110 T108 T107 T106 T104
T111	Condition 2073 2103	Structural brain abnormalities
T112	Procedure 2117 2124	imaging
T113	Temporal 2111 2116	prior
T114	Qualifier 2107 2110	any
R50	Has_qualifier Arg1:T112 Arg2:T114	
R51	Has_temporal Arg1:T112 Arg2:T113	
R52	AND Arg1:T111 Arg2:T112	
T115	Qualifier 2141 2159	clinically evident
T116	Condition 2160 2174	manifestations
R53	Has_qualifier Arg1:T116 Arg2:T115	
R54	AND Arg1:T111 Arg2:T116	
T117	Procedure 2201 2242	transcranial magnetic stimulation studies
T118	Temporal 2176 2183	Current
R55	Has_temporal Arg1:T117 Arg2:T118	
T119	Condition 2253 2275	childbearing potential
T120	Person 2244 2249	Women
T121	Negation 2281 2287	not be
T122	Condition 2288 2296	pregnant
T123	Mood 2298 2316	planning to become
T124	Condition 2317 2325	pregnant
T125	Temporal 2326 2349	during the study period
T126	Condition 2354 2361	nursing
R56	Has_temporal Arg1:T126 Arg2:T125	
R57	Has_mood Arg1:T124 Arg2:T123	
*	OR T124 T126 T122
T127	Scope 2288 2361	pregnant, planning to become pregnant during the study period, or nursing
R58	Has_negation Arg1:T127 Arg2:T121	
T128	Scope 2244 2275	Women of childbearing potential
R59	Has_scope Arg1:T128 Arg2:T127	
T129	Procedure 2364 2399	Participation in a HA support group
T130	Procedure 2426 2436	meditation
T131	Procedure 2440 2444	yoga
T132	Non-representable 2364 2611	Participation in a HA support group or other activity such as meditation or yoga intended to mitigate HA or other chronic pain must be stable at least 4 weeks prior to beginning the initial screen (P1) visit and may not be started during the study
T133	Observation 2613 2638	Failure to record HA data
T134	Multiplier 2639 2663	for at least 80% of days
T135	Temporal 2664 2691	during the Screening Period
R60	Has_multiplier Arg1:T133 Arg2:T134	
R61	Has_temporal Arg1:T133 Arg2:T135	
T136	Non-query-able 2693 2740	Not suitable for study per clinician judgement.
T137	Non-representable 2742 3336	The use of HA rescue or symptom-relieving medications will be allowed during the study. This includes triptans, ergotamines, opioids, simple analgesics (e.g. acetaminophen, aspirin, or non-steroidal anti-inflammatories [NSAIDS], and combination analgesics. Their use will be recorded on the concurrent medication CRF during the Preliminary Screening Period (P1) and throughout the remainder of the study. Randomization of participants will be stratified based on whether their use of HA medications meets ICHD-3 beta criteria for overuse of these medications, as described in section 5.5 below.
T138	Non-representable 3338 3835	Opioid Medications: Use of opioids for treatment of HA or non-HA-related pain or for any other purpose is allowed during the study. Any opioid use would ideally be excluded due to potential confounding effects on interpretation of response to treatment. However, in this population, particularly in Veterans with chronic pain or undergoing minor orthopedic or dental procedures, opioid use is common. Use of opioids, including frequency and dose, will be recorded on the concurrent medication CRF.
T139	Drug 3890 3901	medications
T140	Multiplier 3902 3920	on a routine basis
T141	Qualifier 3934 3945	stable dose
T142	Temporal 3946 4013	for at least 4 weeks prior to the Preliminary Screening Period (P1)
R62	Has_temporal Arg1:T141 Arg2:T142	
T143	Qualifier 3884 3889	other
R63	Has_qualifier Arg1:T139 Arg2:T143	
R64	Has_multiplier Arg1:T139 Arg2:T140	
T144	Scope 3884 3920	other medications on a routine basis
A1	Optional T144
R65	Has_qualifier Arg1:T144 Arg2:T141	
T145	Non-representable 4177 4220	The following medications are not excluded:
T146	Non-representable 4222 4326	Psychoactive drugs (for example, anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics),
T147	Non-representable 4328 4492	Antihypertensive medications (including beta-blockers, calcium channel blockers, angiotensin converting enzyme [ACE] inhibitors, and angiotensin receptor blockers),
T148	Non-representable 4494 4734	The use of magnesium in any dose that is prescribed for the purpose of HA prevention or treatment must be stable for at least 4 weeks. The incidental use of magnesium in multi-vitamins, laxatives, etc. is permissible but must be documented.
T149	Non-representable 4736 4812	Hormones (for example, testosterone, estrogen, or progesterone) in any form.
T150	Non-representable 4814 4988	The "as-needed" (prn) use of psychoactive and other drugs such as antibiotics is not excluded; however, such use must be discussed with a clinician prescriber and documented.
T151	Drug 5001 5011	butalbital
T152	Temporal 5024 5089	within 4 weeks of beginning the Preliminary Screening Period (P1)
R66	Has_temporal Arg1:T151 Arg2:T152	
T153	Non-representable 5163 5534	Participants who have been taking trazodone will undergo a 2-week washout period before the Preliminary Screening Period (P1 visit). Combining prazosin and trazodone may increase the risk of priapism. We have decided to begin the washout period before the Preliminary Screening Period in order to remove any confounding variables while on the headache log and actigraphy.
T154	Drug 5536 5546	Sildenafil
T155	Drug 5548 5554	Viagra
T156	Drug 5557 5566	tadalafil
T157	Drug 5568 5574	Cialis
T158	Drug 5577 5587	vardenafil
T159	Drug 5589 5596	Levitra
T160	Drug 5603 5611	avanafil
T161	Drug 5613 5620	Stendra
R67	Subsumes Arg1:T154 Arg2:T155	
R68	Subsumes Arg1:T156 Arg2:T157	
R69	Subsumes Arg1:T158 Arg2:T159	
R70	Subsumes Arg1:T160 Arg2:T161	
T162	Temporal 5644 5687	during the study drug dose Titration Period
*	OR T154 T156 T158 T160
T163	Scope 5536 5621	Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra)
R71	Has_temporal Arg1:T163 Arg2:T162	
T164	Drug 5930 5938	nitrates
T165	Drug 5966 5976	stimulants
T166	Drug 5986 5993	ephedra
R72	Subsumes Arg1:T165 Arg2:T166	
*	OR T164 T165
T167	Temporal 6012 6063	in the two weeks prior to initial screen (P1) visit
T168	Scope 5930 5994	nitrates and supplements containing stimulants (such as ephedra)
R73	Has_temporal Arg1:T168 Arg2:T167	
T169	Drug 6263 6284	prescribed stimulants
T170	Drug 6294 6305	amphetamine
T171	Drug 6309 6326	dextroamphetamine
*	OR T170 T171
T172	Scope 6294 6326	amphetamine or dextroamphetamine
R74	Subsumes Arg1:T169 Arg2:T172	
T173	Temporal 6367 6420	in the 2 weeks prior to the initial screen (P1) visit
R75	Has_temporal Arg1:T169 Arg2:T173	
